Symbols / APLT
APLT Chart
About
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. As of February 3, 2026, Applied Therapeutics, Inc. operates as a subsidiary of Cycle Group Holdings Limited.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 14.86M |
| Enterprise Value | 5.42M | Income | -18.14M | Sales | 1.00M |
| Book/sh | -0.00 | Cash/sh | 0.08 | Dividend Yield | — |
| Payout | 0.00% | Employees | 28 | IPO | May 14, 2019 |
| P/E | — | Forward P/E | -0.26 | PEG | — |
| P/S | 14.86 | P/B | — | P/C | — |
| EV/EBITDA | -0.05 | EV/Sales | 5.42 | Quick Ratio | 0.87 |
| Current Ratio | 0.96 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.10 | EPS next Y | -0.40 | EPS Growth | — |
| Revenue Growth | 7.20% | Earnings | 2025-11-13 07:00 | ROA | -88.35% |
| ROE | -6.80% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -17.97% | Profit Margin | 0.00% | Shs Outstand | 144.30M |
| Shs Float | 119.83M | Short Float | 2.47% | Short Ratio | 0.30 |
| Short Interest | — | 52W High | 1.50 | 52W Low | 0.09 |
| Beta | 2.08 | Avg Volume | 16.03M | Volume | 2.69M |
| Target Price | — | Recom | Hold | Prev Close | $0.00 |
| Price | $0.10 | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.10
Latest analyst target
3. DCF / Fair value
$-15.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.10
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-03 | down | Leerink Partners | Outperform → Market Perform | $1 |
| 2025-05-14 | reit | RBC Capital | Sector Perform → Sector Perform | $2 |
| 2024-12-23 | down | William Blair | Outperform → Market Perform | — |
| 2024-12-20 | main | RBC Capital | Sector Perform → Sector Perform | $2 |
| 2024-12-02 | down | UBS | Buy → Neutral | $2 |
| 2024-11-29 | main | Citigroup | Buy → Buy | $8 |
| 2024-11-29 | main | Baird | Outperform → Outperform | $5 |
| 2024-11-29 | down | RBC Capital | Outperform → Sector Perform | $4 |
| 2024-11-27 | main | Citigroup | Buy → Buy | $13 |
| 2024-09-19 | main | Citigroup | Buy → Buy | $11 |
| 2024-09-19 | main | Leerink Partners | Outperform → Outperform | $14 |
| 2024-08-27 | main | Citigroup | Buy → Buy | $8 |
| 2024-07-31 | init | William Blair | — → Outperform | — |
| 2024-07-17 | reit | RBC Capital | Outperform → Outperform | $12 |
| 2024-04-11 | reit | RBC Capital | Outperform → Outperform | $12 |
| 2024-03-26 | init | RBC Capital | — → Outperform | $12 |
| 2024-03-15 | main | UBS | Buy → Buy | $13 |
| 2024-03-06 | main | UBS | Buy → Buy | $12 |
| 2024-02-22 | init | Leerink Partners | — → Outperform | $12 |
| 2024-02-16 | main | Citigroup | Buy → Buy | $7 |
- Applied Therapeutics completes merger with Cycle Group Holdings, delists from Nasdaq - Investing.com ue, 03 Feb 2026 08
- Here's Why Applied Therapeutics (APLT) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance ue, 16 Dec 2025 08
- Applied Therapeutics warns: tender now or risk getting nothing - Stock Titan hu, 29 Jan 2026 08
- Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics - Business Wire ue, 03 Feb 2026 08
- Applied Therapeutics Shares Letter to Stockholders - GlobeNewswire hu, 29 Jan 2026 08
- Would You Still Hold Applied Therapeutics Stock If It Fell Another 30%? - Trefis Sun, 21 Dec 2025 08
- Cycle to buy Applied Therapeutics (Nasdaq: APLT) in cash, CVR deal closing in Q1 2026 - Stock Titan hu, 11 Dec 2025 08
- APLT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Applied Therapeutics, Inc. is Fair to Shareholders - The AI Journal Fri, 12 Dec 2025 08
- After losing 87% in the past year, Applied Therapeutics, Inc. (NASDAQ:APLT) institutional owners must be relieved by the recent gain - simplywall.st ue, 07 Oct 2025 07
- Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025) - TechStock² Fri, 12 Dec 2025 08
- Applied Therapeutics Inc. $APLT Shares Sold by Goldman Sachs Group Inc. - MarketBeat ue, 30 Sep 2025 07
- Applied Therapeutics (APLT) Upgraded to Buy: Here's Why - Yahoo Finance hu, 27 Nov 2025 08
- APLT Shares Surge Following Update on AT-007 Trial Plans - GuruFocus Fri, 26 Sep 2025 07
- Are Applied Therapeutics' (APLT) Narrowing Losses a Turning Point for Its Strategic Vision? - simplywall.st Fri, 14 Nov 2025 08
- Analysts Set Applied Therapeutics Inc. (NASDAQ:APLT) Target Price at $6.10 - MarketBeat Sat, 20 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 150000 | — | — | Stock Award(Grant) at price 0.00 per share. | FUNTLEYDER LESLIE D | Chief Financial Officer | — | 2025-12-31 00:00:00 | D |
| 1 | 1187500 | — | — | Stock Award(Grant) at price 0.00 per share. | FUNTLEYDER LESLIE D | Chief Executive Officer | — | 2025-12-19 00:00:00 | D |
| 2 | 437500 | — | — | Stock Award(Grant) at price 0.00 per share. | CHINOPOROS CONSTANTINE | Chief Operating Officer | — | 2025-12-19 00:00:00 | D |
| 3 | 437500 | — | — | Stock Award(Grant) at price 0.00 per share. | BAILEY EVAN PRESCOTT | Officer | — | 2025-12-19 00:00:00 | D |
| 4 | 43000 | 4816 | — | Sale at price 0.11 per share. | KANTER STACY J | Director | — | 2025-12-16 00:00:00 | D |
| 5 | 150000 | — | — | Stock Award(Grant) at price 0.00 per share. | FUNTLEYDER LESLIE D | Chief Financial Officer | — | 2025-10-01 00:00:00 | D |
| 6 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | FUNTLEYDER LESLIE D | Chief Financial Officer | — | 2025-07-01 00:00:00 | D |
| 7 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | BAILEY EVAN PRESCOTT | Officer | — | 2025-06-13 00:00:00 | D |
| 8 | 250000 | — | — | Stock Award(Grant) at price 0.00 per share. | HOOKS CORWIN DALE | Officer | — | 2025-03-24 00:00:00 | D |
| 9 | 350000 | — | — | Stock Award(Grant) at price 0.00 per share. | FUNTLEYDER LESLIE D | Chief Executive Officer | — | 2025-03-24 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -99.09M | -7.61M | -82.44M | -105.20M |
| TotalUnusualItems | -4.78M | -56.57M | -66.00K | |
| TotalUnusualItemsExcludingGoodwill | -4.78M | -56.57M | -66.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -105.62M | -119.76M | -82.51M | -105.58M |
| ReconciledDepreciation | 426.00K | 354.00K | 443.00K | 415.00K |
| EBITDA | -103.87M | -64.18M | -82.51M | -105.20M |
| EBIT | -104.30M | -64.53M | -82.95M | -105.62M |
| NetInterestIncome | 3.53M | 1.37M | 685.00K | 555.00K |
| InterestIncome | 3.53M | 1.37M | 685.00K | |
| NormalizedIncome | -100.84M | -63.19M | -82.44M | -105.58M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -105.62M | -119.76M | -82.51M | -105.58M |
| TotalExpenses | 104.75M | 74.53M | 82.95M | 105.62M |
| TotalOperatingIncomeAsReported | -104.30M | -64.53M | -82.95M | -105.62M |
| DilutedAverageShares | 139.53M | 84.24M | 37.83M | 25.60M |
| BasicAverageShares | 139.53M | 84.24M | 37.83M | 25.60M |
| DilutedEPS | -0.76 | -1.42 | -2.18 | -4.12 |
| BasicEPS | -0.76 | -1.42 | -2.18 | -4.12 |
| DilutedNIAvailtoComStockholders | -105.62M | -119.76M | -82.51M | -105.58M |
| NetIncomeCommonStockholders | -105.62M | -119.76M | -82.51M | -105.58M |
| NetIncome | -105.62M | -119.76M | -82.51M | -105.58M |
| NetIncomeIncludingNoncontrollingInterests | -105.62M | -119.76M | -82.51M | -105.58M |
| NetIncomeContinuousOperations | -105.62M | -119.76M | -82.51M | -105.58M |
| PretaxIncome | -105.62M | -119.76M | -82.51M | -105.58M |
| OtherIncomeExpense | -4.86M | -56.60M | -243.00K | -521.00K |
| OtherNonOperatingIncomeExpenses | -77.00K | -27.00K | -177.00K | -521.00K |
| GainOnSaleOfSecurity | -4.78M | -56.57M | -66.00K | |
| NetNonOperatingInterestIncomeExpense | 3.53M | 1.37M | 685.00K | 555.00K |
| TotalOtherFinanceCost | -685.00K | -555.00K | ||
| InterestIncomeNonOperating | 3.53M | 1.37M | 685.00K | |
| OperatingIncome | -104.30M | -64.53M | -82.95M | -105.62M |
| OperatingExpense | 104.75M | 74.53M | 82.95M | 105.62M |
| ResearchAndDevelopment | 48.74M | 53.91M | 55.63M | 62.57M |
| SellingGeneralAndAdministration | 56.01M | 20.62M | 27.32M | 43.05M |
| GeneralAndAdministrativeExpense | 56.01M | 20.62M | 27.32M | 43.05M |
| OtherGandA | 37.90M | 10.28M | 12.55M | 23.61M |
| InsuranceAndClaims | 1.50M | 2.27M | 3.68M | 4.40M |
| SalariesAndWages | 16.61M | 8.07M | 11.08M | 15.04M |
| TotalRevenue | 455.00K | 9.99M | 0.00 | 0.00 |
| OperatingRevenue | 455.00K | 9.99M | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 137.23M | 84.87M | 48.06M | 26.22M |
| ShareIssued | 137.23M | 84.87M | 48.06M | 26.22M |
| TotalDebt | 2.79M | 777.00K | 1.51M | 2.12M |
| TangibleBookValue | 57.01M | -17.15M | 4.06M | 62.54M |
| InvestedCapital | 57.01M | -16.84M | 4.68M | 63.33M |
| WorkingCapital | 56.35M | -16.80M | 3.88M | 61.93M |
| NetTangibleAssets | 57.01M | -17.15M | 4.06M | 62.54M |
| CapitalLeaseObligations | 2.79M | 467.00K | 891.00K | 1.33M |
| CommonStockEquity | 57.01M | -17.15M | 4.06M | 62.54M |
| TotalCapitalization | 57.01M | -17.15M | 4.06M | 62.54M |
| TotalEquityGrossMinorityInterest | 57.01M | -17.15M | 4.06M | 62.54M |
| StockholdersEquity | 57.01M | -17.15M | 4.06M | 62.54M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 51.00K | -107.00K | |
| OtherEquityAdjustments | 51.00K | -107.00K | ||
| RetainedEarnings | -574.21M | -468.59M | -348.82M | -266.31M |
| AdditionalPaidInCapital | 631.18M | 451.43M | 352.83M | 328.96M |
| CapitalStock | 35.00K | 8.00K | 5.00K | 3.00K |
| CommonStock | 35.00K | 8.00K | 5.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 29.68M | 71.98M | 34.30M | 27.35M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.39M | 797.00K | 878.00K | 891.00K |
| OtherNonCurrentLiabilities | 759.00K | 464.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 2.39M | 38.00K | 414.00K | 891.00K |
| LongTermCapitalLeaseObligation | 2.39M | 38.00K | 414.00K | 891.00K |
| LongTermDebt | 464.00K | |||
| CurrentLiabilities | 27.30M | 71.18M | 33.42M | 26.46M |
| OtherCurrentLiabilities | 6.92M | 54.10M | 14.14M | 987.00K |
| CurrentDeferredLiabilities | 212.00K | 667.00K | 0.00 | |
| CurrentDeferredRevenue | 212.00K | 667.00K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 406.00K | 739.00K | 1.10M | 1.23M |
| CurrentCapitalLeaseObligation | 406.00K | 429.00K | 477.00K | 442.00K |
| CurrentDebt | 310.00K | 622.00K | 789.00K | |
| CurrentNotesPayable | 0.00 | 310.00K | 622.00K | 789.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.02M | 2.07M | 2.30M | 2.78M |
| PayablesAndAccruedExpenses | 15.74M | 13.61M | 15.89M | 21.46M |
| CurrentAccruedExpenses | 11.31M | 11.86M | 11.35M | 12.00M |
| Payables | 4.43M | 1.74M | 4.53M | 9.46M |
| AccountsPayable | 4.43M | 1.74M | 4.53M | 9.46M |
| TotalAssets | 86.69M | 54.83M | 38.36M | 89.89M |
| TotalNonCurrentAssets | 3.04M | 447.00K | 1.05M | 1.50M |
| NonCurrentPrepaidAssets | 253.00K | 0.00 | ||
| NetPPE | 2.79M | 447.00K | 1.05M | 1.50M |
| GrossPPE | 2.79M | 447.00K | 1.05M | 1.50M |
| Leases | 0.00 | 198.00K | 200.00K | |
| OtherProperties | 2.79M | 447.00K | 857.00K | 1.30M |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 83.65M | 54.39M | 37.31M | 88.39M |
| OtherCurrentAssets | 461.00K | 998.00K | 1.75M | 2.09M |
| PrepaidAssets | 3.79M | 3.49M | 4.71M | 4.96M |
| Receivables | 285.00K | 275.00K | 525.00K | |
| TaxesReceivable | 262.00K | 252.00K | 502.00K | |
| AccruedInterestReceivable | 23.00K | 23.00K | 23.00K | |
| CashCashEquivalentsAndShortTermInvestments | 79.40M | 49.90M | 30.58M | 80.82M |
| OtherShortTermInvestments | 0.00 | 13.92M | 26.93M | |
| CashAndCashEquivalents | 79.40M | 49.90M | 16.66M | 53.89M |
| CashEquivalents | 73.23M | 25.01M | 15.32M | 41.22M |
| CashFinancial | 6.17M | 24.89M | 1.34M | 12.67M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -84.31M | -55.17M | -78.09M | -90.73M |
| RepaymentOfDebt | -311.00K | -1.86M | -3.27M | -4.72M |
| IssuanceOfCapitalStock | 104.75M | 64.51M | 27.81M | 74.42M |
| EndCashPosition | 79.40M | 49.90M | 16.66M | 53.89M |
| BeginningCashPosition | 49.90M | 16.66M | 53.89M | 57.47M |
| ChangesInCash | 29.50M | 33.24M | -37.23M | -3.58M |
| FinancingCashFlow | 113.81M | 74.54M | 27.69M | 74.72M |
| CashFlowFromContinuingFinancingActivities | 113.81M | 74.54M | 27.69M | 74.72M |
| NetOtherFinancingCharges | 1.55M | 3.10M | 4.43M | |
| ProceedsFromStockOptionExercised | 9.37M | 10.34M | 49.00K | 580.00K |
| NetCommonStockIssuance | 104.75M | 64.51M | 27.81M | 74.42M |
| CommonStockIssuance | 104.75M | 64.51M | 27.81M | 74.42M |
| NetIssuancePaymentsOfDebt | -311.00K | -1.86M | -3.27M | -4.72M |
| NetShortTermDebtIssuance | -311.00K | -1.86M | -3.27M | -4.72M |
| ShortTermDebtPayments | -311.00K | -1.86M | -3.27M | -4.72M |
| InvestingCashFlow | 0.00 | 13.87M | 13.17M | 12.43M |
| CashFlowFromContinuingInvestingActivities | 0.00 | 13.87M | 13.17M | 12.43M |
| NetInvestmentPurchaseAndSale | 0.00 | 13.87M | 13.17M | 12.43M |
| SaleOfInvestment | 0.00 | 13.87M | 77.39M | 134.02M |
| PurchaseOfInvestment | 0.00 | -64.22M | -121.59M | |
| OperatingCashFlow | -84.31M | -55.17M | -78.09M | -90.73M |
| CashFlowFromContinuingOperatingActivities | -84.31M | -55.17M | -78.09M | -90.73M |
| ChangeInWorkingCapital | 2.52M | -1.44M | -8.84M | -614.00K |
| ChangeInOtherWorkingCapital | -1.55M | -3.10M | -4.43M | |
| ChangeInOtherCurrentLiabilities | -759.00K | 295.00K | 464.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 3.86M | -2.06M | -6.56M | 5.47M |
| ChangeInAccruedExpense | 1.17M | 730.00K | -1.64M | -3.35M |
| ChangeInPayable | 2.69M | -2.79M | -4.93M | 8.82M |
| ChangeInAccountPayable | 2.69M | -2.79M | -4.93M | 8.82M |
| ChangeInPrepaidAssets | -580.00K | 1.87M | 359.00K | -1.65M |
| OtherNonCashItems | 124.00K | 1.74M | 3.15M | -404.00K |
| StockBasedCompensation | 13.47M | 7.36M | 9.60M | 11.18M |
| AmortizationOfSecurities | 3.59M | 4.28M | ||
| DepreciationAmortizationDepletion | 426.00K | 354.00K | 443.00K | 415.00K |
| DepreciationAndAmortization | 426.00K | 354.00K | 443.00K | 415.00K |
| Depreciation | 426.00K | 354.00K | 443.00K | 415.00K |
| OperatingGainsLosses | 4.78M | 56.57M | 66.00K | |
| GainLossOnInvestmentSecurities | 4.78M | 56.57M | 66.00K | |
| NetIncomeFromContinuingOperations | -105.62M | -119.76M | -82.51M | -105.58M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for APLT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|